Novartis Ag (NVS) Change in Receivables (2022 - 2024)
Novartis Ag (NVS) posted Change in Receivables of -$920.0 million for Q1 2024, down 8.24% sequentially from -$850.0 million in Q1 2023, and down 8.24% YoY from -$1.0 billion in Q2 2023.
Novartis Ag (NVS) Change in Receivables (2022 - 2024) Analysis & Trends
Novartis Ag has reported Change in Receivables for 3 years, with the latest figure at -$920.0 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.35 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 1.37 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.09 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 333.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -920.00 Mn |
| Mar 31, 2024 | -920.00 Mn |
| Mar 31, 2023 | -850.00 Mn |
| Mar 31, 2023 | -850.00 Mn |
| Mar 31, 2022 | -496.00 Mn |
| Mar 31, 2022 | -496.00 Mn |